L-dipivaloyl tartaric acid | 1003708-03-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-dipivaloyl tartaric acid
• 英文别名: 2,3-bis(2,2-dimethylpropanoyloxy)butanedioic Acid
• CAS: 1003708-03-9
• 化学式: C₁₄H₂₂O₈
• 分子量: 318.324
• InChiKey: UFHJEZDFEHUYCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS
  申请人：Bayer Aktiengesellschaft

  公开号：US20210163474A1

  公开（公告）日：2021-06-03

  The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and also to the preparation of the enantiomer (Ia) by racemate resolution using chiral substituted tartaric acid esters of the general formulae (IIIa) and (IIIb) where Ar represents a substituted or unsubstituted aromatic or heteroaromatic radical.

  本发明涉及一种用于制备（4S）-4-(4-氰基-2-甲氧基苯基)-5-乙氧基-2,8-二甲基-1,4-二氢-1,6-萘啶-3-羧酰胺（I）的新型改进工艺，以及使用手性取代酒石酸酯（IIIa）和（IIIb）的一般式来进行外消旋分离制备对映体（Ia），其中Ar代表取代或未取代的芳香或杂芳基。
• [EN] HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF<br/>[FR] CINACALCET DE PURETÉ ÉLEVÉE OU L'UN DE SES SELS DE QUALITÉ PHARMACEUTIQUE
  申请人：ACTAVIS GROUP PTC EHF

  公开号：WO2010067204A1

  公开（公告）日：2010-06-17

  Provided herein are impurities of cinacalcet, (R)-α-methyl-N-[3-[3-(trifluoromethyl) phenyl]propyl]-1-(5,6,7,8-tetrahydronaphthalene)methaneamine (tetrahydro cinacalcet impurity), (R)-α-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1- naphthalenemethaneamine-N-oxide (cinacalcet N-oxide impurity) and (R)-α-methyl-N-[3-[3- (trifiuoromethyl)phenyl]methyl]-1-naphthalenemethaneamine (benzylamine impurity); and processes for preparation and isolation thereof. Provided further herein is a highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities.

  本文提供了西那卡塞的杂质，即(R)-α-甲基-N-[3-[3-(三氟甲基)苯基]丙基]-1-(5,6,7,8-四氢萘)甲胺（四氢西那卡塞杂质）、(R)-α-甲基-N-[3-[3-(三氟甲基)苯基]丙基]-1-萘甲胺-N-氧化物（西那卡塞-N-氧化物杂质）和(R)-α-甲基-N-[3-[3-(三氟甲基)苯基]甲基]-1-萘甲胺（苄胺杂质）；以及其制备和分离的方法。此外，本文还提供了一种高纯度的西那卡塞或其在药学上可接受的盐，基本上不含杂质，以及其制备方法和包含高纯度西那卡塞或其在药学上可接受的盐的药物组合物。
• [EN] PROCESS FOR PREPARING CERTAIN CINNAMIDE COMPOUNDS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE CERTAINS COMPOSÉS DE CINNAMIDE
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2010025197A1

  公开（公告）日：2010-03-04

  This invention relates to a new synthesis, intermediates and precursors leading to a mixture of the compounds 11 and 12 as shown below. It also relates to the resolution of the stereoisomeric mixture to provide in substantial stereochemical purity compound 12. The synthesis of the invention involves preparation of compound 7 and compound 10 as shown below and their reaction to prepare a mixture of compound 11 and compound 12.

  这项发明涉及一种新的合成方法，中间体和前体，导致如下所示的化合物11和12的混合物。它还涉及对立体异构物混合物进行分离，以在实质上的立体化学纯度中提供化合物12。该发明的合成涉及制备如下所示的化合物7和化合物10，以及它们的反应以制备化合物11和化合物12的混合物。
• PROCESS FOR PREPARING CERTAIN CINNAMIDE COMPOUNDS
  申请人：Nakamura Taiju

  公开号：US20110172427A1

  公开（公告）日：2011-07-14

  This invention relates to a new synthesis, intermediates and precursors leading to a mixture of the compounds 11 and 12 as shown below. It also relates to the resolution of the stereoisomeric mixture to provide in substantial stereochemical purity compound 12. The synthesis of the invention involves preparation of compound 7 and compound 10 as shown below and their reaction to prepare a mixture of compound 11 and compound 12.

  本发明涉及一种新的合成方法、中间体和前体，可导致化合物11和12的混合物。它还涉及对立体异构混合物的分离，以在实质上立体化学纯度下提供化合物12。该发明的合成涉及制备化合物7和化合物10，如下所示，并将它们反应以制备化合物11和化合物12的混合物。
• HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Sebastian Sonny

  公开号：US20110318417A1

  公开（公告）日：2011-12-29

  Provided herein are impurities of cinacalcet, (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-(5,6,7,8-tetrahydronaphthalene)methaneamine (tetrahydro cinacalcet impurity), (R)-α-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethaneamine-N-oxide (cinacalcet N-oxide impurity) and (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]methyl]-1-naphthalenemethaneamine (benzylamine impurity); and processes for preparation and isolation thereof. Provided further herein is a highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities.

  本文提供了西那卡塞的杂质，包括(R)-α-甲基-N-[3-[3-(三氟甲基)苯基]丙基]-1-(5,6,7,8-四氢萘)甲胺（四氢西那卡塞杂质）、(R)-α-甲基-N-[3-[3-(三氟甲基)苯基]丙基]-1-萘甲胺-N-氧化物（西那卡塞N-氧化物杂质）和(R)-α-甲基-N-[3-[3-(三氟甲基)苯基]甲基]-1-萘甲胺（苄胺杂质）；以及制备和分离它们的过程。本文还提供了高纯度的西那卡塞或其药学上可接受的盐，其基本上不含杂质，以及制备该药物的过程和包含高纯度的西那卡塞或其药学上可接受的盐，其基本上不含杂质的制药组合物。